RxDoctor Payments Data

Daniel Dennis, MD

Plastic Surgery · Mobile, ALNPI 1467434720

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $422 and has fallen 67.6% since, to $137 in 2025. That places this record below the midpoint for plastic surgery clinicians in AL, where the typical reported total is $3,366.

$821in general payments, 2019–2025

Across 42 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Solventum Corporation$139
  • Organogenesis Inc.$126
  • Smith+Nephew$124
  • Polarityte, Inc.$74
  • Baxter Healthcare$45
  • Convatec Inc.$44
  • plus $268 from 13 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$821 in reported general payments places this provider in the 20th percentile of 35 plastic surgery providers in Alabama.

See all plastic surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$101,362
Medicare patients
173
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$19,331
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$206
Clindamycin Hcl12$127
Cephalexin17$88
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$124$19,33112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 35 plastic surgery providers in Alabama.

Other plastic surgery in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →